Every material Form 8-K Entera Bio Ltd. has filed with the SEC since August 18, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Entera Bio reported a third-quarter 2026 net loss of $15.6 million, or $0.11 per share, up from $3.2 million, or $0.07 per share, a year earlier. The company reported no revenue in either period, and the filing attributes the increase mainly to a $7.5 million non-cash fair value remeasurement of pre-funded warrants. Shareholders also got an update that the first clinical site for the EB613 Phase 3 osteoporosis study is expected to be activated in late 2026, with cash of $265.9 million as of September 30, 2026.
Net loss was $15.6 million for the three months ended September 30, 2026, compared with $3.2 million a year earlier.
The loss increase was primarily driven by a $7.5 million non-cash fair value remeasurement of pre-funded warrants.
Research and development expenses rose to $4.9 million from $1.6 million, mainly for EB613 Phase 3 start-up and the OPKO collaboration.
Cash and cash equivalents were $265.9 million as of September 30, 2026, following a July 2026 private placement with gross proceeds of approximately $275.0 million.
Entera Bio's board appointed Dr. Juan Camilo Arjona Ferreira, Head of R&D and Chief Medical Officer at Organon, as a Class II director effective December 1, 2026, and he will join the compensation committee. Director Haya Taitel is stepping down from the board on the same date, and the filing says her departure was not due to any disagreement with the company.
Dr. Arjona Ferreira is the Head of R&D and Chief Medical Officer at Organon & Co. (NYSE: OGN) and previously held roles at Myovant Sciences, Shionogi and Merck & Co.
Board appointment is effective December 1, 2026, and he will serve until the 2027 Annual Meeting of Shareholders.
Haya Taitel notified the board on October 27, 2026 that she will step down as a director effective December 1, 2026.
The board determined Dr. Arjona Ferreira is independent under SEC and Nasdaq rules.
Entera Bio Ltd. appointed biopharmaceutical executive Laura Hamill as a Class I director, effective December 1, 2026, and she will also join the audit and corporate governance and nomination committees. Director Yonatan Malca, who has served the company for 16 years, will step down from the board on the same date. The filing involves board composition only and does not include financial results or guidance.
Laura Hamill, age 62, joins the board effective December 1, 2026, and will serve on the audit and corporate governance and nomination committees.
Hamill was previously Executive Vice President, Worldwide Commercial Operations at Gilead Sciences and spent nearly two decades at Amgen.
Yonatan Malca steps down from the board effective December 1, 2026, and is not leaving over any disagreement with the company.
The Board has determined Hamill is independent under SEC and Nasdaq rules.
Entera Bio appointed Dr. Riccardo Paolo Camisasca as Chief Medical Officer effective August 18, 2026. The company said the hire comes ahead of the planned Phase 3 initiation of its EB613 oral osteoporosis candidate, which it describes as its most advanced product candidate.
Dr. Riccardo Paolo Camisasca appointed Chief Medical Officer, effective immediately on August 18, 2026
Dr. Camisasca has more than 30 years of experience, most recently as Global Head of Research & Development at Sumitomo Pharma Switzerland
Company plans to initiate a Phase 3 program for EB613, its oral PTH(1-34) tablet candidate for osteoporosis
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Entera Bio Ltd. filing is on SEC EDGAR ↗. 8-K briefs of other companies →